Abstract P6-18-24: Lapatinib-based therapies after pertuzumab and/or T-DM1 for HER2+ metastatic breast cancer patients
Simona Frezzini(Istituti di Ricovero e Cura a Carattere Scientifico), Valentina Guarneri(Istituto Oncologico Veneto), Eleonora Mioranza(Istituti di Ricovero e Cura a Carattere Scientifico), Federica Miglietta(University of Padua), Cristina Ghiotto(Istituto Oncologico Veneto), Stefano Angelini, Grazia Maria Vernaci(University of Padua), PierFranco Conte(University of Padua), Alice Menichetti(University of Padua), Tommaso Giarratano(Istituto Oncologico Veneto), CA Giorgi(University of Padua), Giovanni Faggioni(Istituto Oncologico Veneto), Mara Mantiero(University of Padua), Gaia Griguolo(University of North Carolina at Chapel Hill), MV Dieci(University of Padua), Cristina Falci(Istituti di Ricovero e Cura a Carattere Scientifico), Giorgio A. Tasca(University of Padua)
Cited by 0
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830